Американское общество гирудотерапии

Effects of leech therapy on knee osteoarthritis: a randomized clinical trial in an Iranian population

Khoshnevisan A, Sahebkar A, Mohammadpour AH, Mosaffa-Jahromi M (2022) · Journal of Traditional and Complementary Medicine · n=80

RCT evidence detailTrial reference
GRADE LowCohort / case seriesCondition: Knee Osteoarthritis
Sample size of this trial compared with other Knee Osteoarthritis trialsWang H 2018264Lauche R 2025240Lauche R 2014237Farzali S 2025181Cui Y 2024144Andereya S 2008113Andereya S 2008113Sarbaev IS 201996Isik M 201790Khoshnevisan A 202280
This trial (highlighted) by sample size alongside other indexed Knee Osteoarthritis trials. Larger trials generally carry more statistical weight.

Study Profile

Design
single-center, open-label, randomized controlled trial (Mashhad)
Sample size (n)
80
Intervention
Two sessions of 4-6 Hirudo medicinalis leeches, 21 days apart, periarticular knee application
Comparator
Naproxen 500mg twice daily for 6 weeks plus standard knee exercises
Primary endpoint
WOMAC composite score at week 6
Primary result
WOMAC composite reduction 41.2 points in leech vs 23.8 in naproxen at week 6 (between-group difference 17.4 points, p<0.001); effect maintained at week 12
Effect size (Cohen's d)
0.89
Follow-up duration
12 weeks

Key Findings

  • First Iranian RCT for hirudotherapy in knee OA — adds non-European, non-North-American data
  • Compared against oral NSAID (naproxen) rather than topical — more rigorous comparator
  • Effect size consistent with German trials despite different patient population (Iranian, more rural)
  • Inflammation markers (CRP, IL-6) reduced significantly in leech arm — first inflammatory-biomarker RCT data
  • No serious adverse events; mild local pruritus in 22% of leech patients

Limitations

  • Single center, Iran — local Persian medicine context may bias patient expectations
  • Open-label
  • No assessor blinding for WOMAC
  • 6-week comparator phase may underestimate naproxen's sustained effect
  • Biomarker findings exploratory — not powered as primary endpoint

Clinical Implications

Khoshnevisan 2022 extends the knee OA evidence base outside the German/European tradition for the first time at the RCT level. Comparing against oral NSAIDs (the global standard) rather than topical diclofenac strengthens the clinical applicability. The exploratory CRP/IL-6 biomarker data provide preliminary mechanistic confirmation of the anti-inflammatory hypothesis. For US clinicians, this trial adds important external generalizability.

Related Trials

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.